News

TearLab, MellingMedical reach an agreement to enhance early detection of dry eye disease in veterans.

A team of investigators have found that a molecular mechanism drives the progression of uveal melanoma, an often lethal eye cancer in adults.

Researchers found that the effectiveness of the vaccine held for about 6 months in most adults, but began to be less effective at that time point.

Unilateral ptosis can be the first symptom related to other causes that are traumatic, myogenic, neurogenic, or mechanical in nature.

Investigators at Dartmouth College have found that eye contact during a conversation makes the discussion more appealing to its participants.

Lisa Nijm, MD, JD, discusses the brand-new Real World Ophthalmology conference, designed to support ophthalmologists starting practice.

Children’s Hospital of Philadelphia and Stanford University School of Medicine will lead the $5.4 million study ,with patient recruitment beginning in late 2021 or early 2022.

AbbVie and REGENXBIO announced a strategic partnership to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.

Despite varied results, the company will submit a New Drug Application for pegcetacoplan for geographic atrophy to the FDA early next year.

Horizon Therapeutics announced Tuesday the enrollment of the first patient in its Phase 4 clinical trial analyzing TEPEZZA® for the treatment of thyroid eye disease.

OD-OS’s teleguidance offering addresses the lack of experts and also benefits teaching in retina laser care.

The gene-based AAVCOVID vaccine employs a unique adeno-associated viral vector technology that was shown in non-clinical, nonhuman primate studies to enable protection from SARS-CoV-2 challenge and to induce sustained antibody and cellular immune responses from a single dose for up to a year.

Why instillation of topical corticosteroids may be associated with greater ptosis and higher rate of failed ptosis repair

A study in the United Arab Emirates reported a possible link between adverse ocular events and a COVID-19 vaccination.

Researchers believe the vial has the potential to transform the way corneal grafts are preserved and will provide scientists with a platform to develop customized preservation solutions.

Amid a surging COVID-19 pandemic, ophthalmologists in the path of Hurricane Ida are now dealing with the storm's impact.

Organization looks to improve global eye care through ophthalmic education.

According to the Academy and RPB, the grant recipients will use the IRIS Registry database to improve the diagnosis and treatment of eye disease.

Investigators searched PubMed over the past 2 decades for clinical trials on eyelid ptosis using the terms blepharoptosis or upper eyelid ptosis or eyelid ptosis” and the filters “randomized controlled trial (RCT), clinical trial, and humans.”

A team of investigators at McMaster University in Toronto has found that fluvoxamine reduced hospitalizations by up to 30 percent.

Led by eye care nonprofit Orbis with support from Alcon, the training will build eye care professionals' skills to treat retinopathy of prematurity in Latin America

COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.

According to McKinsey’s Hospital Insights Survey, hospital outpatient and procedural volumes were nearly 4 percent higher in July compared to 2019, but ophthalmology was down during the same period.

Regeneron Pharmaceuticals announced at an ongoing Phase 2 trial has met its primary safety endpoint with no new safety signals observed.

Sight Sciences reveals real-world data that show the safety, efficacy, and durability of effect of its Omni Surgical System for use in a standalone procedure to reduce IOP and medication burden.

According to the company, its partnership will educate the gaming community on common dry eye symptoms and introduce over-the-counter options like its Systane brand of eye drops.

The approval could lead hospitals, universities, corporations and even local governents to enact vaccination mandates.

RightEye Sensorimotor is a new technology designed to greatly improve patient care and increase optometry and ophthalmology practice revenue.